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 Synopsis 22 
Objectives: To study the contribution of the multi-drug resistance AcrAB-TolC efflux system 23 
and impact of the efflux inhibitor, PAβN, towards carbapenem resistance in carbapenemase-24 
producing Enterobacteriaceae. 25 
Methods: Klebsiella pneumoniae, Escherichia coli, Salmonella enterica serovar 26 
Typhimurium and their corresponding AcrAB-TolC mutants, each carrying carbapenemase 27 
carrying plasmids (pKpQIL-UK with blaKPC and pNDM-HK with blaNDM), were tested for their 28 
susceptibility to six β-lactam antibiotics according to the BSAC agar dilution method. MICs 29 
were also determined in the presence of efflux inhibitors. The susceptibility of ertapenem in 30 
the presence of 25 and 100 mg/L PAβN was also determined for 86 non-replicate clinical 31 
isolates of carbapenemase-producing Enterobacteriaceae with OXA-48-like (n=18), IMP 32 
(n=12), VIM (n=16), NDM (n=20) or KPC (n=20) enzymes.  Outer membrane protein profiles 33 
were determined with SDS-PAGE. 34 
Results: The carbapenemase producing AcrAB mutants of K. pneumoniae and E. coli, and 35 
TolC mutant of S. Typhimurium had elevated resistance to carbapenem antibiotics. In S. 36 
Typhimurium, the increase in carbapenem MIC correlated with the loss of OmpF. Sixty-two 37 
(72%) of the clinical isolates tested were also more resistant to ertapenem in the presence of 38 
PAβN. SDS-PAGE showed that the presence of PAβN affected outer membrane porin 39 
production, which was associated with the increased MIC values of ertapenem. 40 
Conclusion: The decreased susceptibility to carbapenems of carbapenemase-producing 41 
Enterobacteriaceae in the absence of AcrAB or TolC and/or in the presence of an efflux 42 
inhibitor (e.g. PAβN) is likely due to the changes in porin expression (e.g. OmpF). Efflux 43 
inhibitors may not potentiate carbapenem activity, but rather could increase levels of 44 
resistance in carbapenemase-producing organisms. 45 
  46 
 Introduction 47 
Antibiotic resistance is a major problem worldwide1 and the lack of new efficacious 48 
antibiotics has severely limited the therapeutic options for treating bacterial infections.2 49 
Carbapenems are an important class of antibiotics, increasingly used as a last option in 50 
treating serious bacterial infections.3 Use of these antibiotics has been threatened by the 51 
emergence and dissemination of carbapenemase enzymes which have a broad-spectrum 52 
hydrolytic profile. These carbapenemase enzymes include the Klebsiella pneumoniae 53 
carbapenemase (KPC), New Delhi metallo-β-lactamase (NDM), oxacillinase group β-54 
lactamase (OXA), Verona integron-encoded metallo-β-lactamase (VIM) and imipenemase-55 
type metallo-β-lactamase (IMP)4. Moreover, carbapenemase-producing Enterobacteriaceae 56 
(CPE) are often resistant to other classes of antibiotics, limiting the available therapeutic 57 
options and leading to therapy failure.5 58 
Detection of CPE has traditionally been achieved using phenotypic tests that determine 59 
susceptibility to selected β-lactams; however, these tests can be unreliable. Some isolates of 60 
CPE are inhibited by carbapenem MIC values below recommended breakpoint 61 
concentrations and the clinical implications for treatment with carbapenems are debated. 62 
The CLSI carbapenem breakpoint concentrations were revised in 2010, where isolates 63 
previously classified as carbapenem-susceptible are now classified as carbapenem non-64 
susceptible. However, phenotypic antimicrobial susceptibility testing does not always 65 
demonstrate concordance with carbapenemase activity.6-8 EUCAST (http://www.eucast.org/) 66 
recommends very low cut-off points for identifying potential CPE. The heterogeneity in 67 
carbapenem MIC values observed in CPE may be associated with the diverse combinations 68 
of resistance mechanisms that can be present in each isolate.9 The absence of outer 69 
membrane porin proteins such as the OmpK35 (OmpF homologue) and OmpK36 (OmpC 70 
homologue) have been shown to affect the susceptibility of carbapenemase-producing K. 71 
pneumoniae to carbapenems.10, 11  72 
 The resistance nodulation division (RND) efflux systems found amongst Gram-negative 73 
Enterobacteriaceae confer resistance to many antimicrobial compounds.12  The AcrAB-TolC 74 
efflux system is the best-studied RND efflux system and it extrudes a wide variety of 75 
substrates including different classes of antibiotics. It has been well established that 76 
production of AcrAB-TolC is associated with resistance to some β-lactam antibiotics, 77 
including penicillins and cephalosporins.12 Pages et al. have suggested that there is a 78 
synergistic effect between AcrAB-TolC and β-lactamase enzymes in conferring resistance to 79 
β-lactam antibiotics in K. pneumoniae.13 They showed that various clinical isolates producing 80 
the chromosomal SHV-1 β-lactamase were more susceptible to piperacillin in the presence 81 
of tazobactam (a β-lactamase inhibitor) and PAβN (an efflux inhibitor). In the presence of 82 
tazobactam, the MIC values of piperacillin for the isolates decreased 4- to 8-fold. However, 83 
in the presence of both tazobactam and PAβN, the susceptibility of the isolates increased by 84 
a further 4-fold. The authors suggested that tazobactam was a substrate of the AcrAB-TolC 85 
efflux system, hence, inhibition of the efflux system by PAβN increased the periplasmic 86 
concentration of tazobactam, allowing a stronger protective effect of the β-lactamase 87 
inhibitor on the SHV-1 enzyme.13 However, it has also been shown that inactivation of 88 
AcrAB-TolC in E. coli resulted in a 16-fold increase in susceptibility of the bacterium to 89 
piperacillin.14 Therefore, it is also possible that the larger increase in susceptibility of the K. 90 
pneumoniae isolates to piperacillin in the presence of tazobactam and PAβN was a result of 91 
the combined loss of the functions of the SHV-1 β-lactamase and the efflux system. AcrAB-92 
TolC has also been shown to play an important role in resistance to fluoroquinolones and 93 
triclosan by acting synergistically with other, specific resistance mechanisms for these 94 
agents.15, 16 However, not much is known about the contribution of the AcrAB-TolC efflux 95 
system to carbapenem resistance and any possible synergy with carbapenemases.  96 
In this study, we investigated whether a functional AcrAB-TolC efflux system is required for 97 
full elaboration of resistance towards a variety of clinically important carbapenems in 98 
carbapenemase-producing bacteria. 99 
 Materials and Methods 100 
Bacterial strains, plasmid and growth conditions 101 
All plasmids and bacterial strains used in this study are listed in Table 1. A range of control 102 
strains of different species of Enterobacteriaceae were used to allow comparisons of results 103 
in different species and to utilise panels of well characterised isogenic mutants lacking efflux 104 
pump genes. The rifampicin-resistant mutants of K. pneumoniae Ecl8, K. pneumoniae Ecl8 105 
acrAB::aph, E. coli BW25113, BW25113 acrB::aph, BW25113 tolC::aph and S. Typhimurium 106 
14028s were constructed as previously described using 100 mg/L rifampicin.17 The Ecl8Rif 107 
tolC::aph was generated by inactivating the tolC gene in the rifampicin-resistant Ecl8Rif as 108 
previously described.18 The acrB::aph (EG16566) and tolC::aph (EG16564) alleles were 109 
transduced with P22 into 14028sRif to generate isogenic efflux mutants. The plasmids were 110 
transferred into the various strains using filter-mating.19 All strains constructed were verified 111 
by PCR and DNA sequencing as containing desired genes or mutations (Table 2).  112 
Eighty-six non-replicate clinical isolates of CPE collected from referrals to the AMRHAI 113 
Reference Unit of PHE were studied.  These included Klebsiella oxytoca (n = 4), K. 114 
pneumoniae (n = 25), Enterobacter asburiae (n = 1), Enterobacter aerogenes (n = 3), 115 
Enterobacter cloacae (n = 22), Enterobacter gergoviae (n = 2) and E. coli (n = 29). Each of 116 
these strains carried one of the major carbapenemase genes found in the UK i.e. blaNDM (n = 117 
20) and blaKPC (n = 20), blaOXA-48 –like (n = 18), blaVIM (n = 16), or blaIMP (n = 12).  118 
Determination of antibiotic susceptibility 119 
The minimum inhibitory concentration (MIC) of each antibiotic for the bacterial strains and 120 
clinical isolates was determined using the agar dilution method and interpretation as 121 
described by the BSAC.20 Where efflux inhibitors were tested, the concentrations used were: 122 
phenylalanine-arginine-β-naphthylamide (PAβN; 25 mg/L); 3 µM CCCP; 1-(1-123 
naphthylmethyl)-piperazine (NMP; 100 mg/L). All chemicals were obtained from Sigma-124 
Aldrich, USA.  The MICs were determined on at least two separate occasions. 125 
 Outer membrane protein (porin) extraction and sodium dodecyl sulphate polyacrylamide gel 126 
electrophoresis (SDS-PAGE) 127 
Bacterial outer membrane proteins were purified as previously described.21 Briefly, an 128 
overnight culture of bacteria was incubated at 37°C until it reached an OD600 of 0.6. Cell 129 
pellets were obtained after centrifugation and washing in 50 mM sodium phosphate buffer 130 
pH 7.0, freezing overnight at -80°C. The thawed cell suspension sonicated for 30 seconds 131 
four times with 30-second intervals to avoid overheating and the cell lysates were 132 
centrifuged at 6,000 x g for 1 min at 4°C to discard larger cell debris. The supernatants were 133 
then centrifuged again at 12,000 x g for 30 min at 4°C and pellets re-suspended vigorously 134 
in 200 μL 2% sarcosyl and incubated at room temperature for 30 min. The samples were 135 
centrifuged again at 12,000 x g for 30 min at 10°C. All the supernatant was carefully 136 
removed to ensure most of the detergent containing solution had been removed. The protein 137 
pellet was resuspended in 100 μL of 50 mM sodium phosphate buffer pH 7.0 and 138 
centrifuged at 12,000 x g for 10 min at 4°C to remove residual detergent from the outer 139 
membrane protein preparations. The supernatant was discarded and the extracted outer 140 
membrane proteins were finally resuspended in 50 μL of 50 mM sodium phosphate buffer 141 
pH 7.0. The amount of total protein in each sample was quantified using the Bradford assay.  142 
The extracted outer membrane proteins were separated by SDS-PAGE using 16 x 20 x 0.1 143 
cm discontinuous gels (4% stacking gel and 10 % resolving gel). Sample loading buffer 144 
(Sigma-Aldrich) was added to the protein samples which were heated at 95°C for 10 min. A 145 
total of 2 µg of total protein was loaded per lane for separation. Once the protein samples 146 
had been loaded into the wells, electrophoresis was started using 100 volts (constant) until 147 
the samples migrated into the resolving gel where the voltage was increased to 200 volts. 148 
Gels were stained with PhastGel® Blue R (Sigma-Aldrich) for 1 hour with gentle shaking. 149 
Then, gels were de-stained using de-staining buffer [10% (v/v) methanol and 5% (v/v) acetic 150 
acid in water] overnight with gentle shaking. The de-stained gels were visualised and images 151 
taken a using G:Box Gel Documentation System (Syngene, Cambridge, UK). 152 
 Despite repeated attempts to improve the resolution of the Salmonella porin proteins on SDS 153 
PAGE, this proved challenging. Therefore, to confirm the identity of the protein bands mass 154 
spectrometry was carried out on the bands from gels containing 6 µg of total protein that had 155 
migrated to the molecular sizes typical of OmpC and OmpF. Gel slices were excised from 156 
the gel and processed at the Advanced Mass Spectrometry Facility of the University of 157 
Birmingham. Briefly, bands were subjected to digestion with trypsin and 10µL of extracted 158 
protein in 1% Formic Acid was then used to separate and analyse digested peptides using 159 
an Orbitrap Velos (Thermo Scientific). TurboSEQUEST software (Thermo Scientific) was 160 
used to analyse data and assign protein identities to samples. 161 
   162 
 Results 163 
Inactivation of a gene encoding a component of the AcrAB-TolC efflux pump increases β-164 
lactam resistance 165 
There was no significant difference in the MICs of β-lactam antibiotics for the plasmid-free K. 166 
pneumoniae Ecl8 and its isogenic AcrAB and TolC mutants (Table 3). However, when 167 
pKpQIL-UK carrying blaKPC-2 was present, the AcrAB mutant strain (Ecl8Rif pKPQIL-UK 168 
acrAB::aph) was 8- and 4-fold less susceptible than the parental strain (Ecl8Rif) to ertapenem 169 
and meropenem, respectively. E. coli BW25113 acrB::aph carrying pKpQIL-UK also showed 170 
a 4-fold decrease in susceptibility to ertapenem. However, the E. coli BW25113 TolC mutant 171 
(without plasmid) showed a 4-fold increase in susceptibility to doripenem and biapenem 172 
(when compared to BW25113). This strain carrying pKpQIL-UK (BW25113 pKpQIL-UK 173 
tolC::aph) was also more susceptible to meropenem, doripenem, biapenem and ceftazidime 174 
than BW25113 containing pKpQIL-UK. In contrast to E. coli, S. Typhimurium 14028s 175 
tolC::aph carrying pKpQIL-UK was less susceptible to ertapenem, meropenem, doripenem 176 
and ceftazidime. With the exception of the E. coli TolC mutant, these data suggest that lack 177 
of AcrAB or TolC can increase the MICs of some carbapenems for some Enterobacteriaceae. 178 
To determine whether increased expression of acrAB or tolC in Salmonella affected 179 
carbapenem MICs, pKpQIL-UK was introduced into S. Typhimurium 14028S ramR::aph. No 180 
differences in MIC values to those of 14028s were detected (data not shown). 181 
Decreased susceptibility to β-lactam antibiotics in efflux pump mutants carrying β-182 
lactamases is independent of the vector and β-lactamase gene 183 
To investigate whether the observed decreases in carbapenem susceptibility in the pKpQIL-184 
UK carrying efflux mutants were a specific feature of this plasmid or gene or a general 185 
phenomenon, two other clinically important plasmids (pNDM-HK and pCT) plus a laboratory 186 
vector, pUC18, were introduced into a series of isogenic mutants of S. Typhimurium 14028s 187 
lacking defined efflux components (Table 3). Each plasmid also carried a β-lactamase gene, 188 
 NDM-1, CTX-M-14 and TEM-1, respectively. In the presence of the NDM-1 carrying pNDM-189 
HK, the Salmonella TolC mutant was again 4-fold less susceptible to ertapenem and 190 
meropenem. The presence of pCT in the TolC mutant also decreased its susceptibility to 191 
ceftazidime by 8-fold, but had no affect on the activity of carbapenems. To determine 192 
whether the data obtained with 14028s and mutants was strain specific, the MICs of 193 
antibiotics for S. Typhimurium SL1344 and its isogenic efflux mutants (∆acrA, ∆acrB and 194 
∆tolC) carrying a blaTEM-1 encoding plasmid (pUC18) were also determined. Except for 195 
ertapenem (4-fold less susceptible), no difference was observed in the MIC values for the 196 
various β-lactam antibiotics tested for the TolC mutant, a 4-fold decrease in susceptibility to 197 
biapenem was seen in the AcrAB mutant (Table 3). These data suggest that the reduced 198 
susceptibility to β-lactam antibiotics observed in S. Typhimurium lacking TolC or AcrB is not 199 
specific to the host strain, plasmid or β-lactamase gene it carries. 200 
Efflux inhibitors reduce susceptibility to ertapenem 201 
There are two hypotheses to explain the counter-intuitive observation of reduced 202 
susceptibility to β-lactams seen in the efflux mutants. The phenotype was due to (1) lack of 203 
AcrAB or TolC proteins due to inactivation of acrAB or tolC, or (2) a consequence of loss of 204 
efflux function. To explore the second hypothesis, three efflux inhibitor compounds (PAβN, 205 
CCCP and NMP) with different modes of action were investigated. Ertapenem and the K. 206 
pneumoniae, E. coli and S. Typhimurium strains carrying the pKpQIL-UK plasmid were used 207 
in these experiments. As shown in Table 4, both Salmonella and E. coli pKpQIL-UK carrying 208 
strains (wild-type, AcrB and TolC mutants) was less susceptible to ertapenem in the 209 
presence of both PAβN and NMP. The E. coli TolC mutant was also less susceptible to 210 
ertapenem in the presence of CCCP. No difference in susceptibility was observed in the 211 
presence of various efflux inhibitors for the K. pneumoniae Ecl8Rif carrying the pKpQIL-UK 212 
plasmid. However, in the presence of PAβN, there was a 16- and 4-fold increase in 213 
susceptibility to ertapenem, respectively, for the isogenic K. pneumoniae Ecl8Rif AcrAB and 214 
TolC mutants carrying pKpQIL-UK. 215 
 PAβN increases ertapenem resistance in clinical isolates of Enterobacteriaceae 216 
As our data suggested that PAβN conferred increased resistance to some β-lactam 217 
antibiotics, it was hypothesised that the PAβN effect would be observed with clinical isolates 218 
of carbapenemase producing Enterobacteriaceae.  In the presence of 25 mg/L PAβN, 42% 219 
(n = 36) of the panel of curated CPE isolates became 4-fold or more resistant to ertapenem 220 
(Table 5). A further 30% (n = 26) of the isolates showed a 2-fold increase in ertapenem MIC 221 
values. The remaining isolates (26%, n = 22) showed no change in MIC. When compared 222 
with the ertapenem MICs in the absence of the inhibitor, only two isolates were more 223 
susceptible to ertapenem in the presence of PAβN.  224 
To investigate whether a higher concentration of PAβN would result in a larger number of 225 
clinical isolates showing greater resistance to ertapenem, 100 mg/L PAβN was used. 226 
Interestingly, at this concentration and compared with 25 mg/L PAβN, the number of isolates 227 
for which the ertapenem MIC increased 4-fold was actually reduced to seven (8.1%). A total 228 
of 26 (30.2%) and 33 (38.4%) isolates showed 2-fold increase or no changes in ertapenem 229 
MIC value, respectively. Twenty isolates (ca. 23%) showed more than a 2-fold increase in 230 
ertapenem susceptibility. The 36 isolates for which 25 mg/L PAβN conferred a 4-fold or more 231 
increase in the ertapenem MIC were affected differently when 100 mg/L PAβN was used 232 
(Table 6). At the higher PAβN concentration, only seven of the isolates were 4-fold less 233 
susceptible to ertapenem compared to when no PAβN was added. Of the remaining isolates, 234 
23 were 2-fold less susceptible and 6 isolates had no change in ertapenem MIC value. 235 
PAβN reduces outer membrane protein expression, which is associated with increased 236 
resistance to carbapenems 237 
It was hypothesised that the PAβN effect on the MICs of ertapenem and the other 238 
carbapenems was due to altered expression of outer membrane proteins, possibly porin 239 
proteins. In the presence of the plasmid pKpQIL-UK, the increase in ertapenem MIC value 240 
was more apparent for a mutant lacking OmpF (8-fold increase) and an OmpC-OmpF double 241 
 mutant (16-fold increase) than an OmpC mutant (Table 4). When PAβN was present, this 242 
increase in carbapenem resistance was greater for the S. Typhimurium OmpC mutant (16-243 
fold), than the OmpF and OmpCF mutants (4-fold) (Table 4). In the presence of NMP, a 244 
decrease in susceptibility was also observed in S. Typhimurium SL1344 and its isogenic 245 
OmpC mutant. These data suggest that OmpF plays a more important role than OmpC in 246 
the observed changes in susceptibility to ertapenem. 247 
From the MIC data (Table 4), the loss of outer membrane proteins (OmpC and OmpF) was 248 
associated with the reduction in susceptibility of the S. Typhimurium strains towards 249 
ertapenem. Hence, it was hypothesised that the repression of outer membrane proteins 250 
(OmpC and OmpF) resulted in the reduced β-lactam antibiotic susceptibility in the S. 251 
Typhimurium TolC mutants. Therefore, the expression of outer membrane proteins of the 252 
Salmonella strains in the absence of efflux pump components and when treated with PAβN 253 
were investigated. However, no obvious differences were observed for the efflux pump 254 
mutants compared to the wildtype S. Typhimurium SL1344 SDS-PAGE (Figure 1). 255 
As sixty-two Enterobacteriaceae clinical isolates had reduced susceptibility to ertapenem in 256 
the presence of PAβN (Table 5), it was hypothesised that PAβN altered the outer membrane 257 
and/or porin expression in these isolates, resulting in reduced susceptibility to ertapenem. 258 
Hence, SDS-PAGE of four isolates each of E. coli, Enterobacter spp and five isolates of 259 
Klebsiella which were less susceptible to ertapenem in the presence of 25 mg/L PAβN was 260 
carried out. The outer membrane protein profile of one isolate of each species for which the 261 
ertapenem MIC was not affected by the presence of PAβN was also determined. Isolates 262 
which showed an increase in ertapenem resistance in the presence of PAβN also had 263 
reduced expression of OmpF (or equivalent) when PAβN was added (Figure 2). E. coli 656, 264 
K. pneumoniae 664 and E. asburiae 278 which showed no differences in ertapenem MIC 265 
value when PAβN was added showed no OmpF (or its orthologue) changes. In conclusion, 266 
in the isolates for which PAβN increased ertapenem MIC values, the compound also altered 267 
porin expression.  268 
 Discussion 269 
Previous studies have shown that in E. coli the AcrAB-TolC efflux system works 270 
synergistically with other mechanisms to confer a higher level of resistance to antibacterial 271 
compounds, such as triclosan and ciprofloxacin.15, 16 As a consequence, inhibition of efflux or 272 
deletion of a component of AcrAB-TolC often increases susceptibility to antibiotics. However, 273 
data obtained from our study suggest that a functional AcrAB-TolC is not required for 274 
carbapenem resistance and that AcrAB-TolC does not act synergistically with 275 
carbapenemases. This finding corroborates a previous study which found no increase in 276 
expression of acrB mRNA transcripts among carbapenem-resistant isolates of Klebsiella spp. 277 
and Enterobacter spp.22 Moreover, to date, there is no study that clearly associates 278 
carbapenems (in particular, ertapenem) as a substrate of the AcrAB-TolC efflux system or its 279 
orthologue in P. aeruginosa.  280 
Counter-intuitively, the loss of TolC in S. Typhimurium carrying carbapenemase encoding 281 
plasmids was associated with an increase in the MICs of a variety of carbapenem antibiotics 282 
(ertapenem, meropenem and doripenem) and a cephalosporin (ceftazidime). Although as 283 
expected, the blaTEM-1-encoding pUC18 plasmid did not confer a clinically significant level of 284 
resistance to ertapenem in the Salmonella TolC mutant (SL1344 ∆TolC pUC18), the fold 285 
increase in the ertapenem MIC (when compared with the SL1344 pUC18) was similar to 286 
those shown for strains containing the carbapenemase-encoding plasmids pKpQIL-UK and 287 
pNDM-HK. Taken together, these data suggest that the increase in β-lactam (especially 288 
carbapenem) resistance in the Salmonella TolC mutant was not an artefact of one vector, 289 
nor was it an effect of the specific carbapenemase or β-lactamase. This finding is similar to 290 
those reported for clinical isolates harbouring different carbapenemases and which showed 291 
heteroresistance towards various carbapenem antibiotics.23-25 The addition of the efflux 292 
inhibitor, PAβN, increased the ertapenem MICs for the wild-type S. Typhimurium 14028sRif 293 
and its AcrAB mutant strain. The fold increase was similar to that observed for the 294 
Salmonella TolC mutant carrying the plasmids (in the absence of PAβN). Furthermore, 72 of 295 
 86 clinical isolates showed at least 2-fold increase in ertapenem resistance, in the presence 296 
of PAβN. A similar (8-fold) decrease in ertapenem susceptibility in the presence of 100 mg/L 297 
PAβN has been reported in an E. coli isolate.26 This study showed that the effect of PAβN is 298 
concentration-dependent; with 25 mg/L giving an increase in MICs of antibiotics but a 299 
different impact upon MIC was seen with 100 mg/L. Others have investigated PAβN to 300 
examine the role of efflux in carbapenem resistance when a decrease in carbapenem MIC 301 
was observed in the presence of this efflux inhibitor.26-28 It has been suggested that a low 302 
concentration of PAβN (20 µM ≈ 10.4 mg/L) inhibits efflux, whereas a higher concentration 303 
(0.1 mM ≈ 51.9 mg/L) enhances the rate of efflux of cephalosporins via AcrB29. PAβN has 304 
also been shown to have membrane-permeabilising effects.30, 31 The permeabilising effect of 305 
PAβN may also explain the observation that most of the clinical isolates which showed a 4-306 
fold increase in ertapenem MICs at 25 mg/L PAβN, did not show a significant increase when 307 
100 mg/L of PAβN was used.  308 
Mutation giving increased expression of a global regulator e.g. MarA or RamA gives 309 
increased expression of acrAB and tolC with concomitant repression of porin genes in E. coli, 310 
K. pneumoniae and Salmonella.21, 32, 33 Disruption of the acrB or tolC gene in Salmonella is 311 
also associated with decreased expression of ompF.34 RNA-sequencing of S. Typhimurium 312 
SL1344 after exposure to PAβN also showed decreased ompF mRNA transcript (Blair, JMA. 313 
& Piddock, LJV unpublished data). The ertapenem MICs for the porin mutants carrying 314 
pKpQIL-UK (KPC-2) were increased, with the greatest change seen after addition of PAβN 315 
seen for the OmpC mutant. Taken together, these data suggest that altered porin production 316 
was associated with the observed reduction in ertapenem susceptibility in the efflux mutant 317 
strains carrying the plasmids. This was supported by the SDS-PAGE gels, which showed a 318 
decrease in Salmonella porin expression with an increasing concentration of PAβN. Similar 319 
changes in outer membrane protein profile were observed with the clinical isolates of 320 
Enterobacteriaceae harbouring a variety of carbapenemases. These findings support a 321 
 previous study which showed OmpC and OmpF or their orthologues play a role in 322 
carbapenem resistance among Enterobacter spp. and Klebsiella spp.22 323 
To investigate whether the decrease in carbapenem susceptibility was specific to PAβN, 324 
MICs of ertapenem were determined with two other efflux inhibitors (NMP and CCCP) for S. 325 
Typhimurium 14028sRif carrying the pKpQIL-UK plasmid. This carbapenem was chosen as it 326 
showed the largest change in susceptibility. Independent of the presence of a functional 327 
AcrAB-TolC efflux system, PAβN and NMP reduced the susceptibility of the Salmonella and 328 
E. coli strains harbouring the pKpQIL-UK plasmid. The regulation of porin expression is 329 
known to be complex and differs between species.35, 36 This may explain the differences 330 
observed between the K. pneumoniae, E. coli and S. Typhimurium efflux mutants’ 331 
susceptibility to the antibiotics tested. However, as distinguishing between OmpF and OmpC 332 
on SDS-PAGE was challenging with the Salmonella mutants it is possible that subtle 333 
differences in porin production were not detected. 334 
It is well established that AcrAB-TolC contributes to inherent and acquired antibiotic 335 
resistance and that TolC forms the outer membrane channel of most MDR efflux pumps 336 
found in Enterobacteriaceae. Hence, this system and/or TolC alone have been suggested as 337 
a potential target for efflux inhibitors.37 Our work has shown that addition of PAβN or loss of 338 
a component of a MDR efflux pump such as TolC increased resistance of bacteria against 339 
some antibiotics, which use outer membrane porins as entry routes into the bacterial cell. 340 
Hence, TolC may not be an ideal drug target as the loss of TolC or inhibition of efflux 341 
function may confer increased resistance to some β-lactams. Therefore, we recommend 342 
careful evaluation of new efflux inhibitors to ensure that there is no increased resistance to 343 
clinically important antibiotics in antibiotic resistant bacteria. 344 
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 Table 1. Strains created and plasmids used in this study 488 
Name/Code Description Source 
pKpQIL-UK A blaKPC-2 carrying pKpQIL plasmid isolated in the UK This study 
pNDM-HK A blaNDM-1 carrying plasmid isolated from Hong Kong 38 
pCT A blaCTX-M-14 carrying plasmid isolated from scouring calves 39 
pUC18 A multicopy cloning vector carrying blaTEM-1 40 
Ecl8 K. pneumoniae Ecl8 41 
Ecl8Rif Rifampicin-resistant mutant of Ecl8, His537Leu This study 
Ecl8Rif AcrAB Rifampicin-resistant mutant of Ecl8 acrAB::aph42, His537Leu This study 
Ecl8Rif TolC Ecl8Rif with inactivated outer membrane protein channel (tolC::aph) This study 
Ecl8Rif pKpQIL-UK Ecl8Rif transconjugant carrying pKpQIL-UK This study 
Ecl8Rif AcrAB 
pKpQIL-UK 
Ecl8 Rif acrAB::aph transconjugant carrying pKpQIL-UK This study 
Ecl8Rif TolC 
pKpQIL-UK 
Ecl8 Rif tolC::aph transconjugant carrying pKpQIL-UK This study 
BW25113Rif Rifampicin-resistant mutant of E. coli BW2511343, Pro574Leu This study 
BW25113Rif AcrB Rifampicin-resistant mutant of E. coli BW25113 acrB::aph 43, 
Pro574Leu 
This study 
BW25113Rif TolC Rifampicin-resistant mutant of E. coli BW25113 tolC::aph 43, 
Pro574Leu 
This study 
BW25113Rif 
pKPQIL-UK 
BW25113Rif transconjugant carrying pKpQIL-UK This study 
BW25113Rif AcrB 
pKpQIL-UK 
BW25113Rif acrB::aph transconjugant carrying pKpQIL-UK This study 
BW25113Rif TolC 
pKpQIL-UK 
BW25113Rif tolC::aph transconjugant carrying pKpQIL-UK This study 
14028s Salmonella Typhimurium ATCC14028s ATCC culture 
EG16566 14028s acrAB::cat 44 
EG16564 14028s tolC::cat 44 
14028sRif Rifampicin resistant mutant of S. Typhimurium ATCC14028s, 
Ser522Tyr 
This study 
14028sRif AcrAB Transductant of acrAB::cat from EG16566 into 14028sRif This study 
14028sRif TolC Transductant of tolC::cat from EG16564 into 14028sRif This study 
14028sRif pKpQIL-
UK 
14028sRif carrying the pKpQIL-UK plasmid This study 
14028sRif 
AcrAB/UK 
14028sRif acrAB::cat carrying the pKpQIL-UK plasmid  This study 
14028sRif TolC 
pKpQIL-UK 
14028sRif tolC::cat carrying the pKpQIL-UK plasmid This study 
14028sRif pKpQIL-
UK 
14028sRif carrying the pNDM-HK plasmid This study 
14028sRif AcrAB 
pKpQIL-UK 
14028sRif AcrAB carrying the pNDM-HK plasmid  This study 
14028sRif TolC HK 14028sRif TolC carrying the pNDM-HK plasmid This study 
SL1344 S. Typhimurium strain SL1344 45 
SL1344∆AcrA S. Typhimurium strain SL1344 with inactivated acrA 46 
SL1344∆AcrB S. Typhimurium strain SL1344 with inactivated acrB 47 
SL1344∆TolC S. Typhimurium strain SL1344 with inactivated tolC 47 
SL1344 pUC18 Transformant of SL1344 with the pUC18 plasmid This study 
SL1344∆AcrA 
pUC18 
Transformant of SL1344∆AcrA carrying pUC18 plasmid This study 
SL1344∆AcrB 
pUC18 
Transformant of SL1344∆AcrB carrying pUC18 plasmid This study 
SL1344∆TolC 
pUC18 
Transformant of SL1344∆TolC carrying pUC18 plasmid This study 
  489 
 Table 2. Primers used in this study 490 
Name DNA sequence (5’ to 3’) Description 
KPCg-colpcrF ATGTCACTGTATCGCCGTCT To detect the 
presence of blaKPC  KPCg-colpcrR TAGACGGCCAACACAATAGG 
NDM1-colpcrF TTGATGCTGAGCGGGTG To detect the 
presence of blaNDM  NDM1-colpcrR CTGTCCTTGATCAGGCAGC 
KpTolC-KO-F 
ATACCTATAACAATGGCTATCGCGACAGCA 
ACGGCATCAAGTGTAGGCTGGAGCTGCTTC To inactivate tolC in 
K. pneumoniae 
KpTolC-KO-R 
TAATGTTCAGCTCGTTGATCAGGTAGTTGT 
AGCGCGCATTGGGAATTAGCCATGGTCCAT 
KpEcl8-TolC-F TTTCACCCGCTTCAAT To verify inactivation 
of K. pneumoniae 
tolC KpEcl8-TolC-R GGATTTTTCGAGCTGAAC 
 491 
 492 
 493 
 494 
 495 
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 498 
 499 
 500 
 501 
 502 
 Table 3. MICs of various antibiotics for efflux pump mutants carrying the pKpQIL-UK  (KPC-503 
2), pNDM-HK (NDM-1) or pUC18 plasmids. 504 
Strains Genotype Plasmid Introduced 
Antibiotics (mg/L) 
ETP IPM MEM DOR BIA CAZ 
E. coli 
NCTC10418 
Wild-type - 0.015 0.25 0.03 0.03 0.06 0.25 
K. pneumoniae 
Ecl8 
        
Ecl8Rif RifR - 0.015 0.12 0.015 0.03 0.25 0.03 
Ecl8Rif  acrAB::aph - 0.015 0.12 0.03 0.03 0.25 0.06 
Ecl8Rif tolC::aph  0.015 0.25 0.03 0.06 ND 0.06 
Ecl8Rif RifR pKpQIL-UK 4 4 1 2 4 16 
Ecl8Rif  acrAB::aph pKpQIL-UK 32 8 4 4 8 16 
Ecl8Rif tolC::aph pKpQIL-UK 4 4 2 4 ND 1 
E. coli BW25113         
BW25113Rif RifR - 0.015 0.25 0.03 0.06 0.06 0.06 
BW25113Rif  acrB::aph - 0.015 0.5 0.03 0.06 0.06 0.06 
BW25113Rif  tolC::aph - 0.008 0.12 0.015 0.015 0.015 0.03 
BW25113Rif RifR pKpQIL-UK 0.12 2 0.25 0.5 2 2 
BW25113Rif  acrB::aph pKpQIL-UK 0.5 2 0.25 1 4 2 
BW25113Rif  tolC::aph pKpQIL-UK 0.06 1 0.03 0.12 0.12 0.5 
S. Typhimurium ATCC14028s        
14028s Wildtype - 0.015 0.25 0.03 0.03 0.06 0.25 
14028sRif RifR - 0.008 0.5 0.03 0.03 0.03 0.25 
14028sRif  acrAB::cat - 0.008 0.12 0.015 0.015 0.03 0.12 
14028sRif  tolC::cat - 0.03 0.25 0.03 0.03 0.06 0.5 
14028sRif RifR pKpQIL-UK 2 4 1 1 4 8 
14028sRif  acrAB::cat pKpQIL-UK 2 4 2 1 4 8 
14028sRif  tolC::cat pKpQIL-UK 16 8 8 4 4 32 
14028sRif RifR pNDM-HK 8 8 4 8 2 >512 
14028sRif  acrAB::cat pNDM-HK 8 8 4 4 2 >512 
14028sRif  tolC::cat pNDM-HK 32 16 16 16 1 >512 
14028sRif RifR pCT 0.015 0.125 0.015 0.03 0.03 0.5 
14028sRif  acrAB::cat pCT 0.015 0.125 0.015 0.03 0.03 2 
14028sRif  tolC::cat pCT 0.03 0.25 0.015 0.03 0.03 4 
S. Typhimurium SL1344        
SL1344 Wildtype - 0.03 0.5 0.06 0.125 0.06 2 
SL1344 ∆acrA pUC18 0.03 0.5 0.06 0.125 0.125 2 
SL1344 ∆acrB pUC18 0.03 0.5 0.06 0.125 0.25 2 
SL1344 ∆tolC pUC18 0.12 1 0.12 0.25 0.12 2 
 505 
ETP; Ertapenem; IPM; Imipenem; MEM; meropenem; DOR; doripenem; BIA; biapenem; CAZ; 506 
ceftazidime; Bold font denotes significant increase in MIC values; A consistent >4-fold or more 507 
difference in MIC values between the MIC for the wildtype strain versus the mutant plasmid carrying 508 
strain is indicated with bold font,  are considered significant: ND; Not determined.  509 
 510 
  511 
 Table 4. Ertapenem MICs in the presence of various efflux inhibitors for Enterobacteriaceae 512 
+/- a component of the AcrAB-TolC efflux pump +/- production of KPC-2. 513 
Strains Genotype Plasmid Introduced 
MIC of Ertapenem (mg/L) 
- +PABN +CCCP +NMP 
E. coli 
NCTC10418 Wildtype - 0.015 0.015 0.015 0.015 
K. pneumoniae Ecl8      
Ecl8Rif RifR pKpQIL-UK 4 8 4 4 
Ecl8Rif acrAB::aph pKpQIL-UK 32* 2 32 32 
Ecl8Rif tolC::aph pKpQIL-UK 4 1 1 8 
E. coli BW25113      
BW25113Rif RifR pKpQIL-UK 0.12 1 0.12 0.5 
BW25113Rif acrB::aph pKpQIL-UK 0.5* 4 1 4 
BW25113Rif tolC::aph pKpQIL-UK 0.06 0.25 0.5 0.5 
S. Typhimurium ATCC14028s     
14028sRif RifR pKpQIL-UK 2 32 2 16 
14028sRif  acrAB::cat pKpQIL-UK 1 4 2 8 
14028sRif  tolC::cat pKpQIL-UK 16 0.008 32 64 
S. Typhimurium SL1344      
SL1344Rif RifR pKpQIL-UK 1 8 2 8 
SL1344 ompC::aph pKpQIL-UK 2 32 2 8 
SL1344 ompF::aph pKpQIL-UK 16* 32 16 16 
SL1344 ∆ompC ompF::aph pKpQIL-UK 32* 64 32 32 
 514 
PAβN; phenylalanine-arginine-β-naphthylamide; CCCP; carbonyl cyanide m-chlorophenyl hydrazone; 515 
NMP: 1-(1-naphthylmethyl)-piperazine; Bold font denote significant increase in MIC value in the 516 
presence of an efflux inhibitor. Italic font denotes a significant decrease in MIC value in the presence 517 
of an efflux inhibitor compared with the same strain in the absence of inhibitor. Asterisks (*), indicate 518 
when the MIC of ertapenem for an efflux or porin mutant was increased compared with isogenic 519 
parent strain. The concentrations of PAβN, CCCP and NMP used were 25 mg/L, 3 µM and 100 mg/L, 520 
respectively. 521 
 522 
 523 
 524 
 525 
 526 
  527 
 Table 5. Comparison of the changes in ertapenem resistance between two PAβN 528 
concentrations on 86 carbapenem-resistant clinical isolates of Enterobacteriaceae 529 
 530 
Changes in MIC 
25 mg/L PAβN 100 mg/L PAβN 
Number of 
isolates Percentage (%) 
Number of 
isolates Percentage (%) 
≥4-fold Reduction - - 6 7.0 
2-fold Reduction 2 2.3 14 16.3 
No Change 22 25.6 33 38.4 
2-fold Increase 26 30.2 26 30.2 
≥4-fold Increase 361 41.9 7 8.1 
Total 86 100.0 86 100.0 
 531 
1The impact of 100 mg/L PAβN on these 36 isolates are also shown in Table 6. 532 
The MIC values of ertapenem were determined for 86 non-replicate clinical isolates of 533 
various Enterobacteriaceae (Klebsiella spp., E. coli and Enterobacter spp.), each carrying 534 
one of the five major carbapenemase genes (blaKPC, blaNDM, blaVIM, blaIMP and blaOXA-48) 535 
detected in the UK. 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 Table 6. The impact of 100 mg/L PAβN on the isolates which showed a >4-fold increase in 552 
ertapenem MIC in the presence of 25 mg/L PAβN 553 
Concentration 
The number of isolates (%) with altered ertapenem 
MIC in the presence of PAβN2 
Total 
number 
of 
isolates No Change 2-fold Increase 4-fold Increase 
100 mg/L 6 (16.7) 23 (63.9) 7 (19.4) 36 
 554 
2Change in ertapenem MIC is relative to the MIC of ertapenem in the absence of PAβN. 555 
 556 
 557 
  558 
 Legends to Figures 559 
Figure 1. Outer membrane protein profile of Salmonella Typhimurium SL1344 and its 560 
isogenic efflux pump mutants. Band identities were confirmed by mass spectrometry as 561 
OmpC, OmpD, OmpA and OmpF, respectively. L = PageRuler Plus Prestained Protein 562 
Ladder. 563 
Figure 2. Panel A. Outer membrane proteins of E. coli clinical isolates in the presence and 564 
absence of 25 mg/L PAβN. Panel B. Outer membrane proteins of Klebsiella spp. clinical 565 
isolates in the presence and absence of 25 mg/L PaβN (marked by + and – signs, 566 
respectively). Panel C. Outer membrane proteins of Enterobacter spp. clinical isolates in the 567 
presence and absence of 25 mg/L PaβN (marked by + and – signs, respectively). Values 568 
above the lanes represent the MIC of ertapenem for each strain with or without PAβN.   L = 569 
PageRuler Plus Prestained Protein Ladder. Arrows indicate porins lost upon PAβN exposure 570 
in strains where a decrease in carbapenem susceptibility was also seen (indicated by 571 
asterisks).  572 
 573 
